Covid-19 pushes down growth of pharma

The IPM grew by 0.2 per cent YoY in July (higher 2.4 per cent growth in June) but overall volumes declined by a sharper 6.5 per cent

By   |  Published: 12th Aug 2020  8:39 pm

New Delhi: The Covid-19 pandemic is having a mixed bag for the Indian Pharmaceutical Market (IPM) that registered a muted growth in July on the back of a sharper decline in volumes and higher offtake of trade generic medicines. The IPM grew by 0.2 per cent YoY in July (higher 2.4 per cent growth in June) but overall volumes declined by a sharper 6.5 per cent, an analysis done by Motilal Oswal said.

According to the brokerage report on the healthcare sector, lower growth and volumes in July was offset to some extent by price growth of 4.6 per cent YoY and growth in new launches of 2.2 per cent YoY. The pandemic has brought about major changes in the medication needs of the masses impacting the operation of the pharmaceutical companies with those dealing in respiratory, anti-diabetic, cardiac therapies performing much better than others having anti-infective, gastro, vitamin or pain therapies in their portfolio.

The sudden change in preferred therapies by masses has just taken a sharp turn from the pre-Covid period when gastric, vitamin therapies were most widely used. Probably, the concern that coronavirus impacts adversely chronic heart, lung and diabetics severely had turned people into buying more medicines for these ailments.

In the month of July, cardiac/anti-diabetic/VMN (vitamins, minerals and nutrients) therapies exhibited positive growth of 13.1 per cent YoY/5.9 per cent YoY/5.5 per cent YoY respectively, while anti-infective was down 10.2 per cent YoY (v/s -9.7 per cent YoY in June 2020) while gastro sales dipped 2.4 per cent YoY (v/s flat YoY in June 2020). Pain/analgesics also declined further by 6.7 per cent YoY (v/s -1.9 per cent YoY in June 2020).

In value terms, secondary sales grew one per cent YoY for National list of Essential Medicines or NLEM (16 per cent of IPM) while it remained muted for non-NLEM (84 per cent of IPM) in July. While price growth for the non-NLEM products stood at 4.7 per cent YoY, volumes declined 7.2 per cent YoY. The brokerage report said that in July, Glenmark (+30.3 per cent YoY), JB Chemicals (+12.8 per cent YoY) and Ipca (+11.5 per cent YoY) delivered the highest growth.

Glenmark’s anti-infective segment increased 1.7x YoY, mainly on account of Flabiflu (Covid drug) sales. JB Chemicals grew on the back of robust uptake in its cardiac therapy sales (50.8 per cent of therapy mix), which grew 24.6 per cent YoY. Ipca witnessed good traction in pain/analgesics (+23.4 per cent YoY; 29 per cent of therapy mix) and anti-malaria (+17.8 per cent YoY; 16 per cent of therapy mix) segments.

Sun Pharma’s sales dipped 3.2 per cent YoY (v/s flat YoY growth in June 2020), dragged by decline in anti-infective (-23.8 per cent YoY) and gastro (-10.3 per cent YoY). Glaxo, Natco and Wockhardt exhibited weakest sales at -10.8 per cent/-11.1 per cent/-26.8 per cent YoY respectively in July. Cardiac, anti-malaria and respiratory therapies exhibited the highest growth of 11.1 per cent YoY, 10.5 per cent YoY and 10 per cent YoY on MAT basis in July 2020. However, gynecology (-0.8 per cent YoY) and anti-neoplastic (-2.1 per cent YoY) therapies remained dim.

Natco Pharma Q1 net profit declines 14.5%

New Delhi: Drug firm Natco Pharma on Wednesday reported a 14.49 per cent decline in its consolidated net profit to Rs 122.1 crore for the quarter ended June mainly on account of margin pressure on formulations. The company had posted a net profit of Rs 142.8 crore for the corresponding period of the previous fiscal, Natco Pharma said in a BSE filing. Total income of the company stood at Rs 582.1 crore for the quarter under consideration as against Rs 513.3 crore for the same period year ago, it added.
During the quarter, the company faced margin pressure on both domestic and international formulations, Natco Pharma said. “In spite of lower margins during the first quarter, the company is confident of its business for remaining part of the financial year based on the order book and earnings outlook. The company expects a growth of over 25 per cent in its earnings for FY2020-21 compared to prior year,” it added. The board of directors has approved an interim dividend of Rs 1.25 per equity share of Rs 2 each for FY2020-21, the filing said.